Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Innate Pharma S.A. ADR (NQ: IPHA ) 2.168 -0.102 (-4.48%) Streaming Delayed Price Updated: 1:45 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Innate Pharma S.A. ADR < Previous 1 2 3 4 5 6 7 8 9 Next > Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024 September 30, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors September 23, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Reports First Half 2024 Business Update and Financial Results September 12, 2024 From Innate Pharma SA Via Business Wire Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024 September 09, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update September 05, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference September 04, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces Its Participation in Upcoming Investor Conference August 01, 2024 From Innate Pharma Via Business Wire Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024 July 25, 2024 From Innate Pharma SA Via Business Wire Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024 June 18, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial June 17, 2024 From Innate Pharma SA Via Business Wire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday June 10, 2024 Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning! Via InvestorPlace Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides June 04, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces Its Participation in Upcoming Investor Conferences May 28, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting May 24, 2024 From Innate Pharma SA Via Business Wire Outcome of Innate Pharma’s 2024 Annual General Meeting May 23, 2024 From Innate Pharma SA Via Business Wire Innate Pharma: Clarification Regarding SAR443579 Designation May 21, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress May 15, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Reports First Quarter 2024 Business Update and Financial Results May 14, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update May 07, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients April 15, 2024 From Innate Pharma SA Via Business Wire Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 April 15, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate April 10, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces Its Participation in Upcoming Investor Conference April 09, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F April 05, 2024 From Innate Pharma SA Via Business Wire 12 Health Care Stocks Moving In Wednesday's After-Market Session April 03, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session April 01, 2024 Via Benzinga Innate Pharma Reports Full Year 2023 Financial Results and Business Update March 21, 2024 From Innate Pharma SA Via Business Wire Earnings Scheduled For March 21, 2024 March 21, 2024 Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. Via Benzinga Innate Pharma Announces Its Participation to Upcoming Investor Conference March 19, 2024 From Innate Pharma SA Via Business Wire Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results March 14, 2024 From Innate Pharma SA Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
